Targets › FKBP1A
17 programs from 16 companies in 194 trials: 103 Phase 2, 45 Phase 1, 27 Phase 3, 19 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.
Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. (UniProt, P62942)
Open in Phaseline: the race on FKBP1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Odense University Hospital | Capsule FMT Amiloride-sensitive sodium channel, ENaC blocker | GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1G | Phase 4 | Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women … | Dec 2026 |
| Novartis | everolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 4 | Renal Angiomyolipoma; Tuberous Sclerosis Complex; Advanced Breast Cancer; Renal Cell Carcinoma … | Dec 2026 |
| University Hospital, Limoges | LCP-tacrolimus Calcineurin inhibitor | FKBP1A | Phase 4 | Liver Transplantation | Apr 2028 |
| University Hospital, Limoges | XR-tacrolimus Calcineurin inhibitor | FKBP1A | Phase 4 | Liver Transplantation | Apr 2028 |
| Eisai | Everolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Renal Cell Carcinoma | Mar 2027 |
| Palvella Therapeutics | Sirolimus (PTX-022) FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Pachyonychia Congenita; Cutaneous Venous Malformations; Angiokeratomas | Aug 2027 |
| Mercator MedSystems | Temsirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Peripheral Artery Disease; Alveolar Rhabdomyosarcoma; Advanced Rare Tumours; Endometrial Adenocarcinoma … | Feb 2028 |
| Université de Sherbrooke | CBD Oral Solution FK506-binding protein 1A inhibitor | FKBP1A, PTGS2, IL4R | Phase 3 | Asthma Control; Organ Transplant Failure or Rejection; Fragile X Syndrome; Triple-Negative Breast Cancer | Jul 2028 |
| Jiangsu Simcere Pharmaceutical | Everolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Locally Advanced or Metastatic Breast Cancer | Aug 2028 |
| Rapamycin Holdings | Sirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Familial Adenomatous Polyposis (FAP); Familial Adenomatous Polyposis | Jul 2030 |
| AgelessRx | Sirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Healthspan Improvement; Longevity | – |
| Aadi Bioscience | Sirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 2 | Tumor; Endometrial Cancer; Tumor, Solid | Dec 2026 |
| CSPC ZhongQi Pharmaceutical Technology | Sirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 2 | HR+/HER2- Advanced/Metastatic Breast Cancer; Gastroenteropancreatic Neuroendocrine Tumors; Advanced Solid Tumors; Antiphospholipid (aPL)-Positive … | Oct 2027 |
| Restorbio | Everolimus (RAD001) FK506-binding protein 1A inhibitor | FKBP1A | Phase 2 | Respiratory Tract Infections | – |
| Novaliq | Tacrolimus (NOV05) FK506-binding protein 1A inhibitor | FKBP1A | Phase 2 | Non-infectious Anterior Uveitis; Kidney Transplantation; Kidney Disease, End-Stage; Renal Transplant Recipients … | – |
| Eyestem Research | Tacrolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 1 | Retinal Disease | Dec 2030 |
Aging (6) Sickle Cell Disease (6) Breast Cancer (5) Tuberous Sclerosis Complex (4) Advanced Cancer (4) Liver Transplantation (3) Renal Cell Carcinoma (2) Systemic Lupus Erythematosus (2) Vascular Malformations (2) Lymphatic Malformation (2) Genetic Predisposition to Disease (2) Multiple Myeloma (2)
small molecule (14), mixed (2), protein or peptide (1)
University Hospital, Limoges (2) Eisai (1) CSPC ZhongQi Pharmaceutical Technology (1) Restorbio (1) Novartis (1) Université de Sherbrooke (1) Rapamycin Holdings (1) AgelessRx (1) Novaliq (1) Palvella Therapeutics (1) Jiangsu Simcere Pharmaceutical (1) Aadi Bioscience (1) Odense University Hospital (1) University of Pennsylvania (1) Eyestem Research (1) Mercator MedSystems (1)
TNF (2) PTGS2 (1) IL4R (1) GLP1R (1) ATP4A (1) ATP4B (1) CTLA4 (1) PDCD1 (1) SCNN1A (1) SCNN1B (1) SCNN1G (1) CHRNA4 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.